{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:34:31Z","timestamp":1790768071953,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson\u2019s Research","doi-asserted-by":"publisher","award":["2013-8499"],"award-info":[{"award-number":["2013-8499"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["12-BSV4-0001-01"],"award-info":[{"award-number":["12-BSV4-0001-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Aggregation of \u03b1-synuclein (\u03b1-syn) is the cornerstone of neurodegenerative diseases termed synucleinopathies, which include Parkinson\u2019s Disease (PD), Dementia with Lewy Bodies (DLB), and Multiple System Atrophy (MSA). These synucleinopathies are characterized by the deposit of aggregated \u03b1-syn in intracellular inclusions observable in neurons and glial cells. In PD and DLB, these aggregates, predominantly located in neurons, are called Lewy Bodies (LBs). These LBs are one of the pathological hallmarks of PD and DLB, alongside dopaminergic neuron loss in the substantia nigra. Previous studies have demonstrated the ability of PD patient-derived LB fractions to induce nigrostriatal neurodegeneration and \u03b1-syn pathology when injected into the striatum or the enteric nervous system of non-human primates. Here, we report the pathological consequences of injecting these LB fractions into the cortex of non-human primates. To this end, we inoculated mesencephalic PD patient-derived LB fractions into the prefrontal cortex of baboon monkeys terminated one year later. Extensive analyses were performed to evaluate pathological markers known to be affected in LB pathologies. We first assessed the hypothesized presence of phosphorylated \u03b1-syn at S129 (pSyn) in the prefrontal cortices. Second, we quantified the neuronal, microglial, and astrocytic cell survival in the same cortices. Third, we characterized these cortical LB injections\u2019 putative impact on the integrity of the nigrostriatal system. Overall, we observed pSyn accumulation around the injection site in the dorsal prefrontal cortex, in connected cortical regions, and further towards the striatum, suggesting \u03b1-syn pathological propagation. The pathology was also accompanied by neuronal loss in these prefrontal cortical regions and the caudate nucleus, without, however, loss of nigral dopamine neurons. In conclusion, this pilot study provides novel data demonstrating the toxicity of patient-derived extracts, their potential to propagate from the cortex to the striatum in non-human primates, and a possible primate model of DLB.<\/jats:p>","DOI":"10.1038\/s41531-023-00579-w","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T11:02:38Z","timestamp":1695121358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cortical Lewy body injections induce long-distance pathogenic alterations in the non-human primate brain"],"prefix":"10.1038","volume":"9","author":[{"given":"Margaux","family":"Teil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Dovero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Bourdenx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Arotcarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgane","family":"Darricau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Porras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"Thiolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Trigo-Damas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Perier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Garcia-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4953-1446","authenticated-orcid":false,"given":"Mar\u00eda Trinidad","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1352-989X","authenticated-orcid":false,"given":"Miquel","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Obeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0410-4638","authenticated-orcid":false,"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-9045","authenticated-orcid":false,"given":"Benjamin","family":"Dehay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"579_CR1","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"579_CR2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/B978-0-444-53491-0.00019-5","volume":"117","author":"GK Wenning","year":"2013","unstructured":"Wenning, G. K. & Krismer, F. Multiple system atrophy. Handb. Clin. Neurol. 117, 229\u2013241 (2013).","journal-title":"Handb. Clin. Neurol."},{"key":"579_CR3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3390\/biom10030391","volume":"10","author":"M Teil","year":"2020","unstructured":"Teil, M. et al. Targeting alpha-synuclein for PD therapeutics: a pursuit on all fronts. Biomolecules 10, 391 (2020).","journal-title":"Biomolecules"},{"key":"579_CR4","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","volume":"95","author":"MG Spillantini","year":"1998","unstructured":"Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M. & Goedert, M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with Lewy bodies. Proc. Natl Acad. Sci. USA 95, 6469\u20136473 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"579_CR5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"key":"579_CR6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00401-011-0852-9","volume":"122","author":"GM Halliday","year":"2011","unstructured":"Halliday, G. M., Holton, J. L., Revesz, T. & Dickson, D. W. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol. 122, 187\u2013204 (2011).","journal-title":"Acta Neuropathol."},{"key":"579_CR7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1126\/science.1195227","volume":"329","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9, J. et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329, 1663\u20131667 (2010).","journal-title":"Science"},{"key":"579_CR8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jchemneu.2010.12.001","volume":"42","author":"F Cheng","year":"2011","unstructured":"Cheng, F., Vivacqua, G. & Yu, S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat. 42, 242\u2013248 (2011).","journal-title":"J. Chem. Neuroanat."},{"key":"579_CR9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.brainresrev.2011.03.002","volume":"67","author":"CE Chua","year":"2011","unstructured":"Chua, C. E. & Tang, B. L. Rabs, SNAREs and alpha-synuclein\u2013membrane trafficking defects in synucleinopathies. Brain Res. Rev. 67, 268\u2013281 (2011).","journal-title":"Brain Res. Rev."},{"key":"579_CR10","doi-asserted-by":"crossref","first-page":"9364","DOI":"10.1523\/JNEUROSCI.4787-13.2014","volume":"34","author":"KJ Vargas","year":"2014","unstructured":"Vargas, K. J. et al. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J. Neurosci. 34, 9364\u20139376 (2014).","journal-title":"J. Neurosci."},{"key":"579_CR11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","volume":"14","author":"JH Kordower","year":"2008","unstructured":"Kordower, J. H., Chu, Y., Hauser, R. A., Freeman, T. B. & Olanow, C. W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson\u2019s disease. Nat. Med. 14, 504\u2013506 (2008).","journal-title":"Nat. Med."},{"key":"579_CR12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.nbd.2011.05.001","volume":"43","author":"JH Kordower","year":"2011","unstructured":"Kordower, J. H. et al. Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiol. Dis. 43, 552\u2013557 (2011).","journal-title":"Neurobiol. Dis."},{"key":"579_CR13","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/brain\/awt037","volume":"136","author":"M Masuda-Suzukake","year":"2013","unstructured":"Masuda-Suzukake, M. et al. Prion-like spreading of pathological alpha-synuclein in brain. Brain 136, 1128\u20131138 (2013).","journal-title":"Brain"},{"key":"579_CR14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-018-0104-4","volume":"557","author":"C Peng","year":"2018","unstructured":"Peng, C. et al. Cellular milieu imparts distinct pathological alpha-synuclein strains in alpha-synucleinopathies. Nature 557, 558\u2013563 (2018).","journal-title":"Nature"},{"key":"579_CR15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak, H. et al. Staging of brain pathology related to sporadic Parkinson\u2019s disease. Neurobiol. Aging 24, 197\u2013211 (2003).","journal-title":"Neurobiol. Aging"},{"key":"579_CR16","doi-asserted-by":"crossref","first-page":"E5308","DOI":"10.1073\/pnas.1514475112","volume":"112","author":"SB Prusiner","year":"2015","unstructured":"Prusiner, S. B. et al. Evidence for alpha-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc. Natl Acad. Sci. USA 112, E5308\u2013E5317 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"579_CR17","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrn.2016.178","volume":"18","author":"DJ Surmeier","year":"2017","unstructured":"Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101\u2013113 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"579_CR18","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3389\/fphar.2020.00356","volume":"11","author":"M Gomez-Benito","year":"2020","unstructured":"Gomez-Benito, M. et al. Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front. Pharm. 11, 356 (2020).","journal-title":"Front. Pharm."},{"key":"579_CR19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrn.2017.75","volume":"18","author":"JB Koprich","year":"2017","unstructured":"Koprich, J. B., Kalia, L. V. & Brotchie, J. M. Animal models of alpha-synucleinopathy for Parkinson disease drug development. Nat. Rev. Neurosci. 18, 515\u2013529 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"579_CR20","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00441-017-2730-9","volume":"373","author":"A Recasens","year":"2018","unstructured":"Recasens, A., Ulusoy, A., Kahle, P. J., Di Monte, D. A. & Dehay, B. In vivo models of alpha-synuclein transmission and propagation. Cell Tissue Res. 373, 183\u2013193 (2018).","journal-title":"Cell Tissue Res."},{"key":"579_CR21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/biomedicines9030272","volume":"9","author":"M Teil","year":"2021","unstructured":"Teil, M., Arotcarena, M. L. & Dehay, B. A new rise of non-human primate models of synucleinopathies. Biomedicines 9, 272 (2021).","journal-title":"Biomedicines"},{"key":"579_CR22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.14802\/jmd.19046","volume":"12","author":"HK Chung","year":"2019","unstructured":"Chung, H. K., Ho, H. A., Perez-Acuna, D. & Lee, S. J. Modeling alpha-synuclein propagation with preformed fibril injections. J. Mov. Disord. 12, 139\u2013151 (2019).","journal-title":"J. Mov. Disord."},{"key":"579_CR23","doi-asserted-by":"crossref","first-page":"106086","DOI":"10.1016\/j.nbd.2023.106086","volume":"180","author":"A Fayard","year":"2023","unstructured":"Fayard, A. et al. Functional and neuropathological changes induced by injection of distinct alpha-synuclein strains: a pilot study in non-human primates. Neurobiol. Dis. 180, 106086 (2023).","journal-title":"Neurobiol. Dis."},{"key":"579_CR24","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/brain\/awaa096","volume":"143","author":"ML Arotcarena","year":"2020","unstructured":"Arotcarena, M. L. et al. Bidirectional gut-to-brain and brain-to-gut propagation of synucleinopathy in non-human primates. Brain 143, 1462\u20131475 (2020).","journal-title":"Brain"},{"key":"579_CR25","doi-asserted-by":"crossref","first-page":"eaaz9165","DOI":"10.1126\/sciadv.aaz9165","volume":"6","author":"M Bourdenx","year":"2020","unstructured":"Bourdenx, M. et al. Identification of distinct pathological signatures induced by patient-derived alpha-synuclein structures in nonhuman primates. Sci. Adv. 6, eaaz9165 (2020).","journal-title":"Sci. Adv."},{"key":"579_CR26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/ana.24066","volume":"75","author":"A Recasens","year":"2014","unstructured":"Recasens, A. et al. Lewy body extracts from Parkinson disease brains trigger alpha-synuclein pathology and neurodegeneration in mice and monkeys. Ann. Neurol. 75, 351\u2013362 (2014).","journal-title":"Ann. Neurol."},{"key":"579_CR27","doi-asserted-by":"crossref","first-page":"e13584","DOI":"10.1111\/acel.13584","volume":"21","author":"ML Arotcarena","year":"2022","unstructured":"Arotcarena, M. L. et al. Acidic nanoparticles protect against alpha-synuclein-induced neurodegeneration through the restoration of lysosomal function. Aging Cell 21, e13584 (2022).","journal-title":"Aging Cell"},{"key":"579_CR28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/brain\/awab374","volume":"145","author":"M Teil","year":"2022","unstructured":"Teil, M. et al. Brain injections of glial cytoplasmic inclusions induce a multiple system atrophy-like pathology. Brain 145, 1001\u20131017 (2022).","journal-title":"Brain"},{"key":"579_CR29","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/nan.12678","volume":"47","author":"M Deffains","year":"2020","unstructured":"Deffains, M. et al. L-DOPA regulates alpha-synuclein accumulation in experimental Parkinsonism. Neuropathol. Appl. Neurobiol. 47, 532\u2013543 (2020).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"579_CR30","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1523\/JNEUROSCI.22-07-02780.2002","volume":"22","author":"D Kirik","year":"2002","unstructured":"Kirik, D. et al. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 22, 2780\u20132791 (2002).","journal-title":"J. Neurosci."},{"key":"579_CR31","doi-asserted-by":"crossref","first-page":"29739","DOI":"10.1074\/jbc.M600933200","volume":"281","author":"JP Anderson","year":"2006","unstructured":"Anderson, J. P. et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281, 29739\u201329752 (2006).","journal-title":"J. Biol. Chem."},{"key":"579_CR32","doi-asserted-by":"crossref","first-page":"10211","DOI":"10.1074\/jbc.M809671200","volume":"284","author":"CL Kragh","year":"2009","unstructured":"Kragh, C. L. et al. Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J. Biol. Chem. 284, 10211\u201310222 (2009).","journal-title":"J. Biol. Chem."},{"key":"579_CR33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/44.10.8813082","volume":"44","author":"HK Wolf","year":"1996","unstructured":"Wolf, H. K. et al. NeuN: a useful neuronal marker for diagnostic histopathology. J. Histochem. Cytochem. 44, 1167\u20131171 (1996).","journal-title":"J. Histochem. Cytochem."},{"key":"579_CR34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3389\/fncel.2013.00003","volume":"7","author":"A Karperien","year":"2013","unstructured":"Karperien, A., Ahammer, H. & Jelinek, H. F. Quantitating the subtleties of microglial morphology with fractal analysis. Front. Cell. Neurosci. 7, 3 (2013).","journal-title":"Front. Cell. Neurosci."},{"key":"579_CR35","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/hmg\/ddx120","volume":"26","author":"FN Soria","year":"2017","unstructured":"Soria, F. N. et al. Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration. Hum. Mol. Genet. 26, 2603\u20132615 (2017).","journal-title":"Hum. Mol. Genet."},{"key":"579_CR36","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cne.20323","volume":"479","author":"T Gonzalez-Hernandez","year":"2004","unstructured":"Gonzalez-Hernandez, T., Barroso-Chinea, P., De La Cruz Muros, I., Del Mar Perez-Delgado, M. & Rodriguez, M. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J. Comp. Neurol. 479, 198\u2013215 (2004).","journal-title":"J. Comp. Neurol."},{"key":"579_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41531-023-00514-z","volume":"9","author":"C Pifl","year":"2023","unstructured":"Pifl, C., Reither, H., Attems, J. & Zecca, L. Dopamine and vesicular monoamine transport loss supports incidental Lewy body disease as preclinical idiopathic Parkinson. npj Parkinsons Dis. 9, 89 (2023).","journal-title":"npj Parkinsons Dis."},{"key":"579_CR38","first-page":"414","volume":"54","author":"L Zecca","year":"2001","unstructured":"Zecca, L. et al. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol. Pathol. 54, 414\u2013418 (2001).","journal-title":"Mol. Pathol."},{"key":"579_CR39","first-page":"256","volume":"95","author":"CD Marsden","year":"1961","unstructured":"Marsden, C. D. Pigmentation in the nucleus substantiae nigrae of mammals. J. Anat. 95, 256\u2013261 (1961).","journal-title":"J. Anat."},{"key":"579_CR40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41583-020-00416-6","volume":"22","author":"MB Fares","year":"2021","unstructured":"Fares, M. B., Jagannath, S. & Lashuel, H. A. Reverse engineering Lewy bodies: how far have we come and how far can we go? Nat. Rev. Neurosci. 22, 111\u2013131 (2021).","journal-title":"Nat. Rev. Neurosci."},{"key":"579_CR41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41583-021-00542-9","volume":"23","author":"J Blesa","year":"2022","unstructured":"Blesa, J., Foffani, G., Dehay, B., Bezard, E. & Obeso, J. A. Motor and non-motor circuit disturbances in early Parkinson disease: which happens first? Nat. Rev. Neurosci. 23, 115\u2013128 (2022).","journal-title":"Nat. Rev. Neurosci."},{"key":"579_CR42","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1093\/brain\/awz296","volume":"142","author":"Y Chu","year":"2019","unstructured":"Chu, Y. et al. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain 142, 3565\u20133579 (2019).","journal-title":"Brain"},{"key":"579_CR43","doi-asserted-by":"crossref","first-page":"9497","DOI":"10.1523\/JNEUROSCI.5806-12.2014","volume":"34","author":"BB Averbeck","year":"2014","unstructured":"Averbeck, B. B., Lehman, J., Jacobson, M. & Haber, S. N. Estimates of projection overlap and zones of convergence within frontal-striatal circuits. J. Neurosci. 34, 9497\u20139505 (2014).","journal-title":"J. Neurosci."},{"key":"579_CR44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2016.18.1\/shaber","volume":"18","author":"SN Haber","year":"2016","unstructured":"Haber, S. N. Corticostriatal circuitry. Dialogues Clin. Neurosci. 18, 7\u201321 (2016).","journal-title":"Dialogues Clin. Neurosci."},{"key":"579_CR45","doi-asserted-by":"crossref","first-page":"10999","DOI":"10.1523\/JNEUROSCI.23-35-10999.2003","volume":"23","author":"E Bezard","year":"2003","unstructured":"Bezard, E. et al. Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors. J. Neurosci. 23, 10999\u201311007 (2003).","journal-title":"J. Neurosci."},{"key":"579_CR46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0301-0082(98)00006-9","volume":"55","author":"E Bezard","year":"1998","unstructured":"Bezard, E. & Gross, C. E. Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach. Prog. Neurobiol. 55, 93\u2013116 (1998).","journal-title":"Prog. Neurobiol."},{"key":"579_CR47","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1046\/j.1460-9568.2000.00180.x","volume":"12","author":"E Bezard","year":"2000","unstructured":"Bezard, E. et al. Adaptive changes in the nigrostriatal pathway in response to increased 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration in the mouse. Eur. J. Neurosci. 12, 2892\u20132900 (2000).","journal-title":"Eur. J. Neurosci."},{"key":"579_CR48","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.expneurol.2012.01.011","volume":"246","author":"RE Burke","year":"2013","unstructured":"Burke, R. E. & O\u2019Malley, K. Axon degeneration in Parkinson\u2019s disease. Exp. Neurol. 246, 72\u201383 (2013).","journal-title":"Exp. Neurol."},{"key":"579_CR49","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1523\/JNEUROSCI.5519-10.2011","volume":"31","author":"HC Cheng","year":"2011","unstructured":"Cheng, H. C. et al. Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J. Neurosci. 31, 2125\u20132135 (2011).","journal-title":"J. Neurosci."},{"key":"579_CR50","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1212\/WNL.51.2_Suppl_2.S2","volume":"51","author":"O Hornykiewicz","year":"1998","unstructured":"Hornykiewicz, O. Biochemical aspects of Parkinson\u2019s disease. Neurology 51, S2\u2013S9 (1998).","journal-title":"Neurology"},{"key":"579_CR51","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ana.21995","volume":"67","author":"HC Cheng","year":"2010","unstructured":"Cheng, H. C., Ulane, C. M. & Burke, R. E. Clinical progression in Parkinson disease and the neurobiology of axons. Ann. Neurol. 67, 715\u2013725 (2010).","journal-title":"Ann. Neurol."},{"key":"579_CR52","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1002\/mds.27823","volume":"34","author":"YC Wong","year":"2019","unstructured":"Wong, Y. C. et al. Neuronal vulnerability in Parkinson disease: should the focus be on axons and synaptic terminals? Mov. Disord. 34, 1406\u20131422 (2019).","journal-title":"Mov. Disord."},{"key":"579_CR53","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1126\/science.aan8868","volume":"358","author":"M Carlen","year":"2017","unstructured":"Carlen, M. What constitutes the prefrontal cortex? Science 358, 478\u2013482 (2017).","journal-title":"Science"},{"key":"579_CR54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41386-021-01156-6","volume":"47","author":"SN Haber","year":"2022","unstructured":"Haber, S. N., Liu, H., Seidlitz, J. & Bullmore, E. Prefrontal connectomics: from anatomy to human imaging. Neuropsychopharmacology 47, 20\u201340 (2022).","journal-title":"Neuropsychopharmacology"},{"key":"579_CR55","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.celrep.2015.01.060","volume":"10","author":"VR Osterberg","year":"2015","unstructured":"Osterberg, V. R. et al. Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism. Cell Rep. 10, 1252\u20131260 (2015).","journal-title":"Cell Rep."},{"key":"579_CR56","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1084\/jem.20112457","volume":"209","author":"KC Luk","year":"2012","unstructured":"Luk, K. C. et al. Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. J. Exp. Med. 209, 975\u2013986 (2012).","journal-title":"J. Exp. Med."},{"key":"579_CR57","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s40478-020-01026-0","volume":"8","author":"AJ Schaser","year":"2020","unstructured":"Schaser, A. J. et al. Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy. Acta Neuropathol. Commun. 8, 150 (2020).","journal-title":"Acta Neuropathol. Commun."},{"key":"579_CR58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.3233\/JPD-212566","volume":"11","author":"SW Boutros","year":"2021","unstructured":"Boutros, S. W., Raber, J. & Unni, V. K. Effects of alpha-synuclein targeted antisense oligonucleotides on Lewy body-like pathology and behavioral disturbances induced by injections of pre-formed fibrils in the mouse motor cortex. J. Parkinsons Dis. 11, 1091\u20131115 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"579_CR59","doi-asserted-by":"crossref","first-page":"136273","DOI":"10.1016\/j.neulet.2021.136273","volume":"765","author":"Q Zhang","year":"2021","unstructured":"Zhang, Q. et al. Cortical alpha-synuclein preformed fibrils do not affect interval timing in mice. Neurosci. Lett. 765, 136273 (2021).","journal-title":"Neurosci. Lett."},{"key":"579_CR60","doi-asserted-by":"crossref","first-page":"135051","DOI":"10.1016\/j.neulet.2020.135051","volume":"733","author":"LM Wagner","year":"2020","unstructured":"Wagner, L. M., Nathwani, S. M., Ten Eyck, P. P. & Aldridge, G. M. Local cortical overexpression of human wild-type alpha-synuclein leads to increased dendritic spine density in mouse. Neurosci. Lett. 733, 135051 (2020).","journal-title":"Neurosci. Lett."},{"key":"579_CR61","first-page":"185","volume":"3","author":"K Kosaka","year":"1984","unstructured":"Kosaka, K., Yoshimura, M., Ikeda, K. & Budka, H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree\u2013a new disease? Clin. Neuropathol. 3, 185\u2013192 (1984).","journal-title":"Clin. Neuropathol."},{"key":"579_CR62","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00690978","volume":"42","author":"K Kosaka","year":"1978","unstructured":"Kosaka, K. Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol. 42, 127\u2013134 (1978).","journal-title":"Acta Neuropathol."},{"key":"579_CR63","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1046\/j.1440-1789.2000.00301.x","volume":"20 (Suppl.)","author":"K Kosaka","year":"2000","unstructured":"Kosaka, K. Diffuse Lewy body disease. Neuropathology 20 (Suppl.), S73\u2013S78 (2000).","journal-title":"Neuropathology"},{"key":"579_CR64","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archneurol.2012.1608","volume":"69","author":"PT Kotzbauer","year":"2012","unstructured":"Kotzbauer, P. T. et al. Pathologic accumulation of alpha-synuclein and Abeta in Parkinson disease patients with dementia. Arch. Neurol. 69, 1326\u20131331 (2012).","journal-title":"Arch. Neurol."},{"key":"579_CR65","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.expneurol.2007.11.019","volume":"210","author":"K Obi","year":"2008","unstructured":"Obi, K. et al. Relationship of phosphorylated alpha-synuclein and tau accumulation to Abeta deposition in the cerebral cortex of dementia with Lewy bodies. Exp. Neurol. 210, 409\u2013420 (2008).","journal-title":"Exp. Neurol."},{"key":"579_CR66","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1006\/nimg.2002.1197","volume":"17","author":"EJ Burton","year":"2002","unstructured":"Burton, E. J. et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 17, 618\u2013630 (2002).","journal-title":"Neuroimage"},{"key":"579_CR67","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1471-4159.2001.00021.x","volume":"76","author":"BC Campbell","year":"2001","unstructured":"Campbell, B. C. et al. The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson\u2019s disease. J. Neurochem. 76, 87\u201396 (2001).","journal-title":"J. Neurochem."},{"key":"579_CR68","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1007\/s004010051135","volume":"99","author":"E Gomez-Tortosa","year":"2000","unstructured":"Gomez-Tortosa, E., Newell, K., Irizarry, M. C., Sanders, J. L. & Hyman, B. T. Alpha-synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. 99, 352\u2013357 (2000).","journal-title":"Acta Neuropathol."},{"key":"579_CR69","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/exnr.2002.7961","volume":"177","author":"M Sakamoto","year":"2002","unstructured":"Sakamoto, M. et al. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alpha-synuclein, ubiquitin, and thiazin red. Exp. Neurol. 177, 88\u201394 (2002).","journal-title":"Exp. Neurol."},{"key":"579_CR70","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1093\/brain\/awx275","volume":"140","author":"M Colom-Cadena","year":"2017","unstructured":"Colom-Cadena, M. et al. Synaptic phosphorylated alpha-synuclein in dementia with Lewy bodies. Brain 140, 3204\u20133214 (2017).","journal-title":"Brain"},{"key":"579_CR71","doi-asserted-by":"publisher","unstructured":"Laurens, J. The statistical power of three monkeys. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2022.05.10.491373 (2022).","DOI":"10.1101\/2022.05.10.491373"},{"key":"579_CR72","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3390\/biom12020228","volume":"12","author":"E Bezard","year":"2022","unstructured":"Bezard, E. How lazy reading and semantic sloppiness may harm progress in synucleinopathy research. Biomolecules 12, 228 (2022).","journal-title":"Biomolecules"},{"key":"579_CR73","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-17328-9","volume":"11","author":"FN Soria","year":"2020","unstructured":"Soria, F. N. et al. Synucleinopathy alters nanoscale organization and diffusion in the brain extracellular space through hyaluronan remodeling. Nat. Commun. 11, 3440 (2020).","journal-title":"Nat. Commun."},{"key":"579_CR74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1749-6632.1996.tb39062.x","volume":"786","author":"T Iwatsubo","year":"1996","unstructured":"Iwatsubo, T. et al. Lewy bodies: purification from diffuse Lewy body disease brains. Ann. N. Y Acad. Sci. 786, 195\u2013205 (1996).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"579_CR75","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00001756-200001170-00041","volume":"11","author":"NW Kowall","year":"2000","unstructured":"Kowall, N. W. et al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 11, 211\u2013213 (2000).","journal-title":"Neuroreport"},{"key":"579_CR76","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0361-9230(98)00128-2","volume":"47","author":"DA McRitchie","year":"1998","unstructured":"McRitchie, D. A. et al. The midbrain dopaminergic cell groups in the baboon Papio ursinus. Brain Res. Bull. 47, 611\u2013623 (1998).","journal-title":"Brain Res. Bull."},{"key":"579_CR77","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41592-019-0470-3","volume":"16","author":"J Ho","year":"2019","unstructured":"Ho, J., Tumkaya, T., Aryal, S., Choi, H. & Claridge-Chang, A. Moving beyond P values: data analysis with estimation graphics. Nat. Methods 16, 565\u2013566 (2019).","journal-title":"Nat. Methods"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00579-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00579-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00579-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T05:14:30Z","timestamp":1700284470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-023-00579-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["579"],"URL":"https:\/\/doi.org\/10.1038\/s41531-023-00579-w","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"5 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.B. is a director and shareholder of Motac Neuroscience Ltd. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"135"}}